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Nm23 expression in endometrial and cervical cancer: inverse correlation
with lymph node involvement and myometrial invasion
M Marone,1, G Scambia', G Ferrandinal, C Giannitellil, P Benedetti-Panicil, S lacovellal,
A Leone2 and S Mancuso'
'Department of Obstetrics and Gynaecology, Catholic University, 00168 Rome; 2Laboratorio di Oncologia Sperimentale, Istituto
Oncologico di Bari, 70124 Bari, Italy.
Summary The expression of nm23 has been shown to correlate in some solid tumours with their metastatic
potential and to be associated with a favourable prognosis in human breast cancer and melanoma. In breast
and ovarian cancer nm23 expression is also correlated with lymph node involvement. We analysed the
expression of nm23-HI and -H2 in normal endometrium and in endometrial and cervical cancer by both
Northern and Western blotting. Cellular localisation of Nm23-HI was visualised by immunohistochemistry
mostly in the cytoplasm. Both isoforms of Nm23 were present in all the samples analysed, and a clear direct
correlation between Nm23-H1 and -H2 levels was evident. Median nm23-H2 levels were higher than than -H1
levels in both tissues. Cervical cancer patients with lymph node involvement were shown to have significantly
lower protein levels of Nm23 (P<0.007 for HI and P<0.009 for H2), and a similar trend was also evident in
endometrial cancer. Furthermore, the degree of myometrial invasion in endometrial cancer patients was also
inversely correlated with Nm23-H1 levels of expression (P<0.003). Nm23 level may therefore be taken into
consideration as a new marker in the prognostic characterisation and in the treatment planning of uterine
tumour patients.
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Although conflicting results have been obtained in different
solid tumours, nm23 is usually classified as a putative
metastasis-suppressor gene. Originally isolated by differential
hybridisation between two related murine melanoma cell lines
distinguished by their metastatic potential (Steeg et al., 1988),
Nm23-H1 has been identified with the A subunit of
erythrocyte nucleoside diphosphate kinase (NDPK) (Gilles
et al., 1991). A second human gene, nm23-H1, was later
identified whose product bears 88% amino acid identity with
Nm23-H1 and codes for the B subunit ofNDPK (Stahl et al.,
1991). Cloning of a third gene, designated nm23-H3b has
been reported recently (Jiang et al., 1994), indicating that we
may be in the presence of a multigene family and of a
complex regulatory mechanism.
Despite the high degree of homology between HI and H2,
the two proteins differ in structure and function. H2 contains
a putative leucine zipper motif (Stahl et al., 1991) and has
been identified with both the c-myc transcription factor PuF
(Postel et al., 1993) and with the I-factor (differentiation
inhibiting factor) purified from mouse myeloid leukaemia
cells (Okabe-Kado et al., 1992) and is clearly a bifunctional
molecule whose NDPK activity is not required for DNA
binding, nor for in vitro transcriptional activity (Postel and
Ferrone, 1994).
It is well established that nm23-H1 and more questionably
-H2 are involved in tumour metastasis control. A decrease in
nm23-HI RNA was observed in highly metastatic tumour
cells from various rodent systems (Steeg et al., 1988) and
transfection of the H cDNA in murine melanoma and
human breast cancer cells was shown to cause a reduction of
cell migration in response to serum and defined growth
factors and a reduction of tumour metastatic potential 'in
vivo' (Leone et al., 1991, 1993a).
The biochemical mechanisms by which nm23 acts in
metastatic processes have not been clarified yet. NDPK
activity of nm23 has been reported as unrelated to its
metastasis-suppressor effects (Leone et al., 1991), while other
biochemical functions of nm23 have been described
(Nickerson and Wells, 1984; Ohtsuki et al., 1986; Walton
and Gill, 1975; Lombardi et al., 1995; Howlett et al., 1994).
Autophosphorylation of serine 44 seems to be directly
associated with suppression of metastatic potential in nm23-
Hi-transfected murine melanoma cells (MacDonald et al.,
1993).
A favourable clinical significance of nm23 overexpression
has been reported in breast (Bevilacqua et al., 1989),
hepatocellular (Nakayama et al., 1992), prostate (Konishi et
al., 1993), and gastric cancer (Nakayama et al., 1993) and in
melanoma (Florenes et al., 1992). However, metastatic spread
and progression have been correlated with overexpression in
colon carcinoma (Myeroff and Markowitz, 1993) and
neuroblastoma (Leone et al., 1993b). Therefore, it has been
hypothesised that nm23 may play a tissue-specific role and
that different regulatory mechanisms may act in different
tumours. Moreover, an inverse correlation between nm23
levels and lymph node involvement in breast cancer has been
shown for HI and not for H2, thus suggesting a different role
for the two genes (Tokunaga et al., 1993).
The role of nm23 in gynaecological tumours has not been
extensively investigated yet. It has been reported that ovarian
cancer patients with metastatic lymph node involvement have
lower nm23 levels than lymph node-negative cases (Mandai et
al., 1994; Scambia et al., 1996). Moreover, we demonstrated
that the overexpression of nm23-H 1 is associated with
survival advantage and greater likelihood of response to
chemotherapy in patients with advanced ovarian cancer
(Scambia et al., 1996). A recent study reported the absence
of nm23 mutations in endometrial cancer (Ambros et al.,
1994) but did not address the clinicopathological correlation
of mRNA/protein levels.
In the present study nm23-H1 and nm23-H2 levels were
analysed both by Northern and Western blotting in two
different series ofendometrial and cervical tumour samples to
determine their possible association with clinicopathological
parameters.
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Materials and methods
Patients and sample collection
This study was conducted on a total of 13 normal
endometria, 45 endometrial and 40 cervical cancer samples
taken from patients admitted to the Department of
Gynaecology of the Catholic University of Rome. Normal
endometrial samples were as follows: three post-menopausal,
five in the proliferative and five in the secretory phase of the
cell cycle.
All cancer patients were staged according to the FIGO
classification (Petterson, 1988) and their tumours were graded
as well (GI), moderately (G2) or poorly (G3) differentiated
(World Health Organization, 1979).
Myometrial invasion was classified as Ml when tumour
infiltration was <50% of myometrial thickness or M2 when
it exceeded 50%. Patients were treated by abdominal
hysterectomy plus bilateral salpingo-oophorectomy. The
cervical cancer patients received cisplatin-based neoadjuvant
chemotherapy followed by radical surgery (Benedetti-Panici
et al., 1991) or conventional exclusive radiotherapy.
Tissues were frozen in liquid nitrogen immediately after
surgery and stored at -80°C until processed. The presence of
uterine cervical tumour and endometrial tumour was
confirmed by histopathological analysis.
Immunohistochemical analysis
Immunohistochemical analysis of Nm23-H1 was performed
on three cervical and three endometrial cancers with the
mouse anti-human nm23/NDP kinase-A monoclonal anti-
body (Ylem, Avezzano, Italy) and the avidin-biotin-perox-
idase complex detection method (Ylem). At the time of
surgery tumours were dissected and fixed for 24 h in neutral
buffered formalin. Following fixation blocks were paraffin
embedded. Sections (5 gm) were dewaxed in xylene,
rehydrated in descending concentrations of alcohol down to
80%, washed in water and treated with 0.3% hydrogen
peroxide in methanol for 5 min to remove endogenous
peroxidase activity. The sections were then washed in Tris-
buffered saline pH 7.6 (TBS) and incubated with normal
serum as the blocking reagent to minimise non-specific
binding. A 1:100 dilution of the specific anti-human Nm23
MAb was applied for 1 h at room temperature. Normal
mouse IgG (Sigma) was used as the negative control. The
sections were then incubated with the biotinylated goat anti-
mouse IgG and with avidin-biotin-peroxidase complex for
20 min at room temperature. Finally, the sections were
washed in TBS, stained by incubation with amino-9-
ethylcarbazole in N, N'-dimethylformamide in acetate buffer
plus 0.01% hydrogen peroxide for 20 min and counterstained
with haematoxylin.
Probes
The specific 3' untranslated regions for nm23-H1 and nm23-
H2 were labelled with 32P by random priming (Amersham
random priming labelling kit) as described earlier (Stahl et
al., 1991). Specific activity was 2.1 +0.4 x 109 d.p.m. jug-' for
nm23-HIA and 1.8+0.2 x 109 for nm23-H2. A human f-actin
full-length cDNA probe was used as internal control to
confirm the amount of RNA loaded in each lane.
RNA samples and Northern blotting analysis
Total RNA was obtained by the method of Chomczynsky et
al. (1987). Total RNA (20 ug) was separated on 1.2%
agarose gels in 2.2 M formaldehyde, capillary-transferred to
nylon filters (Duralon, Stratagene, La Jolla, CA, USA) and
UV-crosslinked. Duplicate filters were made for hybridisation
with the specific nm23-HI and -H2 probes.
Hybridisation was performed at 42°C for 18 h in 50%
formamide, 5 x saline sodium citrate (SSC), 1 x Denhardt's
solution, 0.2% sodium dodecylsulphate (SDS) and
200 pig ml-' denaturated salmon sperm DNA, with
1 x 106d.p.m./ml-' of the specific probe (Sambrook et al.,
1989). After washing, blots were exposed to 3 M XDA plus
Trimax films at -80°C with intensifying screens for 6 days.
The blots were subsequently rehybridised with
0.5 x 106 d.p.m./ml-IP-actin probe and exposed to radio-
graphic film for 24 h. Nm23 relative intensity was measured
by densitometry on an LKB XL laser densitometer
(Pharmacia LKB Biothecnology, Uppsala, Sweden) and the
numbers obtained were normalised to the corresponding /1-
actin values.
Preparation of the tissue lysates and Western blotting analysis
Frozen tumour tissues were pulverised and homogenised as
described earlier (Scambia et al., 1993). The protein
concentration was determined using the Bio-Rad Protein
Assay (Bio-Rad Laboratories, Hercules, CA, USA).
Aliquots of 50 Mg of each protein sample were separated
onto a 15% SDS-polyacrylamide gel and electroblotted onto
a nitrocellulose membrane (Bio-Rad Laboratories), (Ausubel
et al., 1994). After electroblotting the membranes were
incubated with 6% non-fat dry milk in 1 x TBST (0.1 M
Trizma base, 0.15 M sodium chloride, 0.05% Tween 20,
pH 7.4) for blocking and then with a 1:300 dilution of rabbit
polyclonal anti-Nm23 antibody (a gift from Dr P S Steeg,
NCI, Bethesda, MD, USA) in 3% non-fat dry milk in
1 x TBST. Following incubation with a 1: 2000 dilution with
an alkaline phosphatase-conjugated goat anti-rabbit anti-
body, visualisation of the bound antibody was performed
with 5-bromo-4-chloro-3-indolyl-phosphate (BCIP, Sigma)
and nitroblue tetrazolium [NBT, Sigma, (Knecht and
Dimond, 1984)]. Duplicate gels were run for all the samples
and stained with Coomassie blue for control. Samples
showing degradation bands were eliminated from the series.
Densitometric quantitation of the intensity of the bands
corresponding to Nm23-H1 and -H2 was performed on an
LKB XL laser densitometer as described above.
Statistical analysis
Pearson's correlation test was used to analyse the relationship
between Nm23-H1 and Nm23-H2 levels ofexpression and the
Mann-Whitney non-parametric test was used to analyse the
relationship between Nm23 and clinicopathological charac-
teristics of the patients and the distribution of oestrogen
receptor (ER), progesterone receptor (PR), epidermal growth
factor receptor (EGFR) and p21 levels.
Results
Immunohistochemical localisation ofNm23 in human
endometrial and cervical cancer
Figure 1 shows the typical immunohistochemical staining
pattern for Nm23 in cervical (Figure la) and endometrial
cancer (Figure lb). Staining was evident in the epithelial and
not in the stromal component of both tissues and was mostly
cytoplasmic.
Northern and Western blotting analysis
Twenty-four endometrial and 19 cervical tumour samples
were analysed by Northern blotting. Figure 2 is a
representative Northern blot panel showing the signal
obtained on duplicate filters for nm23-H1, -H2 and the
corresponding ,B-actin band in cervical (lanes 1-3) and
endometrial cancer samples (lanes 4-6). Both nm23-HI and -
H2 mRNAs were present at detectable levels in all the
samples analysed. Median densitometric values of band
intensity on Northern blot were 0.18 (range 0.01-4.89) for
HI and 0.82 (range 0.08-3.13) for H2 in endometrium, and
0.19 (range 0.01-4.50) for HI and 0.79 (range 0.21-15.37)
for H2 in cervix (Table I). In both the tissues examined theExpression of nm23 in endometrial and cervical cancer
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Figure 1 Immunohistochemical analysis of nm23-H in primary
cervical (a) and endometrial cancer (b) with the avidin-biotin-
peroxidase complex method. Staining is evident in the epithelial
component of both tissues. Original magnification x 200.
nm23-H2 levels were significantly higher than -H1 (P<0.003
in endometrial and P <0.002 in cervical cancer).
Thirteen normal, 21 tumour endometrial samples and 21
tumour cervical samples were analysed by Western blotting
using an anti-Nm23 polyclonal antibody. Two bands of 18.5
and 17 kDa corresponding to Nm23-H1 and Nm23-H2
respectively, were visible in all samples as shown in Figure
3 in a representative blot. The measured densitometric values
are shown in Table I. Median Nm23-H2 values were
significantly higher than -H11 (P<0.0004 for normal
,B-Actin 3-Actin
Figure 2 Representative Northern blot of endometrial and
cervical cancer samples. Duplicate blots were hybridised with
the specific nm23-Hl and -H2 probes and later reprobed with ,B-
actin as control. a, nm23-H1; b, nm23-H2; c and d are the same
blots reprobed with ,B-actin. Lanes 1, 2 and 3 are cervical tumour
samples; lanes 3, 4, 5 and 6 are endometrial tumour samples.
Table I Median and range values obtained for nm23-Hl and -H2 in
cervical and endometrial samples
Type of mm-Ha nm23-H2a
analysis Tissue n Median Range Median Range
Northern Endometrial 24 0.18 0.01-4.89 0.82 0.08-3.13
blot cancer 19 0.19 0.01-4.50 0.79 0.21-15.37
Cervical cancer
Western Normal 13 1.05 0.15-4.45 1.54 0.05-4.63
blot endometrium
Proliferative 5 1.14 0.35-2.72 2.37 0.99-4.63
Secretory 5 0.90 0.15-2.90 0.64 0.05-3.71
Atrophic 3 1.09 0.52-4.45 1.30 0.68-3.54
Endometrial 21 0.90 0.01-3.78 1.78 0.06-6.75
cancer
Cervical cancer 21 0.40 0.06-3.57 0.92 0.08-5.82
anm23 relative intensity was measured by densitometry as described
in Materials and methods.
endometrium, P<0.0001 in endometrial and cervical
cancer). In normal endometrium, all the samples which were
in the secretory phase of the cycle had similar levels of HI
and H2 (median 0.64 and 0.90 respectively), while the
samples in the proliferative phase had a tendency towards
higher median values for H2 (2.37) than for HI (1.14). A statistically significant correlation between the levels of
expression of Nm23-H1 and -H2 was measured both by Northern and Western blot. The data obtained at the mRNA
level is shown in Figure 4a (r=0.907, P<0.0001, in
endometrial samples; r =0.964, P<0.0001, in cervical
samples). At the protein level the correlation was also
evident in all the groups (r =0.778, P<0.0004, in normal
endometrial samples; r=0.754, P<0.0001 in endometrial
cancer; r=0.933, P<0.0001, in cervical cancer, Figure 4b).
Nm23 and clinicopathological characteristics
The distribution of Nm23 proteins according to clinicopatho- logical characteristics is shown in Table II. In cervical cancer
a clear inverse correlation was evident between lymph node
involvement and the levels ofNm23-HI and -H2. The median
level of expression for H1 was 1.77 for lymph node-negative (N-) samples vs 0.37 in lymph node-positive (N+) cases
(z=2.680, P<0.007). An inverse correlation is evident also
for H2, with a median value of 2.47 in N- and 0.13 in N+
samples (z=2.608, P<0.009). Although the difference was
not statistically significant, a similar trend was shown in
Ml-Expression of nm23 in endometrial and cervical cancer
M Marone et al
1066
endometrial cancer, in which N- samples have a median of
1.73 vs N+ samples with a median of 0.70 (P<0.221) for HI
and 1.46 in N- and 0.64 in N+ patients for H2 (P<0.142).
Moreover, patients with myometrial invasion <50% showed
higher levels of Nm23 (HI median value= 1.92, H2= 1.65)
than those with myometrial invasion >50% (Hi =0.46,
P<0.003; H2=0.85, P<0.101).
No correlation was shown with stage or grade of
differentiation (Table II). Also, no significant correlation
was found between Nm23 levels and ER, PR, EGFR and ras-
p21 levels (data not shown).
product (Liotta and Steeg, 1990), which displays NDPK
activity and is involved in normal cell differentiation and
development.
Contrary to ovarian and gastrointestinal cancer (Scambia
et al., 1996; Nakayama et al., 1993) and malignant melanoma
(Florenes et al., 1992), in which nm23 expression was found
6
5
Discussion
The present study is the first report which analyses the
expression of nm23-H1 and -H2 in normal and neoplastic
uterine tissues both at the mRNA and protein levels. Nm23
was present in all the samples analysed, including normal
endometrium suggesting that nm23 is likely to play the role
of a 'housekeeping' gene involved in the normal cell
functions. This is consistent with the finding that Nm23 is
highly conserved in evolution and bears up to 75% identity
with the Drosophila abnormal wing discs (AWD) gene
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Figure 3 Immunoblotting analysis of Nm23-HI and -H2
expression in cervical cancer, and in endometrial normal and
cancer tissues. The blot was reacted with anti-Nm23 polyclonal
antibodies which recognise both HI (higher band, rm 18.5 kDa)
and H2 (lower band, rm 17.5 kDa). Lanes 1, 2, 4 and 5 are
endometrial tumour samples; lane 3 is normal endometrium; lanes
6, 7 and 8 are cervical tumour samples.
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Figure 4 Correlation between the relative intensities of nm23-H1
and -H2 obtained by Northern blot (a) and Western blot (b).
Table II Distrubution of densitometric values of nm23-H1 and -H2 obtained by Western blot according to histopathological characteristics in
endometrial and cervical carcinoma
nm23-Hla nm23-H2a
n Mean Median s.d. Range Mean Median s.d. Range
Endometrial cancer
Stage
I 16 1.66 1.40 1.20 0.40-3.78 2.38 1.48 2.00 0.19-6.75
III, IV 5 0.94 0.97 0.43 0.10-1.72 0.51 0.47 0.20 0.06-1.02
Grading
1 11 1.81 1.40 1.21 0.10-3.78 2.01 1.55 1.73 0.06-4.60
2 6 1.42 1.79 0.9 0.40-2.48 2.00 1.02 2.7 0.19-6.75
3 4 1.43 0.49 1.66 0.46-3.36 1.94 0.93 1.82 0.85-4.05
Lymph-node status
5 1.72 1.79 1.034 0.55-2.98 2.21 1.46 2.60 0.19-6.75
+ 4 0.70 0.81 0.46 0.10- 1.08 0.60 0.65 0.41 0.06-1.05
Myometrial invasion
<50 13 2.09 1.92a 0.98 0.55-3.78 2.44 1.65c 2.17 0.19-6.75
>50 6 0.47 0.46 0.28 0.10-0.90 0.73 0.85 0.56 0.06-1.50
Cervical cancer
Stage
I,jI 8 0.85 0.75 0.72 0.12-2.17 1.02 0.46 1.44 0.12-3.88
III 6 0.28 0.29 0.17 0.06-0.52 0.27 0.31 0.16 0.08-0.44
IV 7 1.36 1.19 1.28 0.08-3.57 1.67 0.81 2.21 0.08-5.82
Grading
1 10 0.61 0.52 0.72 0.08-2.17 0.80 0.44 1.36 0.08-3.88
2 7 1.10 1.01 0.55 0.40-1.77 1.13 0.95 0.91 0.08-2.47
3 4 0.24 0.29 0.16 0.06-0.37 0.27 0.31 0.17 0.08-0.42
Lymph-node status
5 1.98 1.77 1.06 0.63- 3.57 2.76 2.47e 2.15 0.50-5.82
+ 7 0.41 0.37 0.36 0.06-0.59 0.30 0.13 0.27 0.08-0.78
anm23 relative intensity was measured by densitometry as described in Materials and methods; bp<0.003;Cp<0.101;dp< 0.007 ep< 0.009. The
P-values were determined by the Mann Whitney non-parametric test.
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to be higher in tumours compared with normal tissues
(Scambia et al., 1996), we found no differences in nm23 levels
between normal and carcinomatosous endometrium. This
finding suggests that nm23 does not play a significant role in
endometrial tumour carcinogenesis.
Since nm23-H1 has been reported as the gene which is
more directly correlated with the metastatic potential, most
of the data which have been published so far dealt with HI
more than H2. No extensive analysis has been published to
date on the relative distribution of the two genes and
although H2 has been identified with the PuF transcription
factor (Postel et al., 1993) and with the I-factor (Okabe-Kado
et al., 1992), its role remains unclear.
In our series of samples the level of H2 was, on average,
significantly higher than HI, at both mRNA and protein
level. In particular the Western blots performed with
polyclonal antibodies, which recognise both isoforms as two
bands of different molecular weights, make it possible to
measure the relative intensity of HI and H2 at the same time
in the same sample, allowing us to make a direct comparison.
These results differ from the data obtained in ovarian tissues
(Scambia et al., 1996), thus indicating the possibility that H2
may play a more important role in endometrium and cervix
than in other tissues of the female genital tract. H2 has been
reported as a very abundant message in breast cancer as well
(Tokunaga et al., 1993). A clear direct correlation was
observed between the levels of expression of HI and H2. A
direct correlation has been reported earlier in ovarian and
colon cancer (Mandai et al., 1994; Myeroff and Markowitz,
1993; Scambia et al., 1996), but has not been observed in
other tissues. In breast cancer, for example, HI and H2 levels
are not correlated with each other and only HI is related to
prognosis (Tokunaga et al., 1993). This suggests that different
regulatory pathways, which control the absolute and relative
levels of HI and H2, may act in different tissues.
At present the clinical significance of nm23 in different
malignancies has been poorly investigated. As far as
gynaecological tumours are concerned, we have demon-
strated that nm23-H1 expression has an independent
favourable prognostic role in ovarian cancer (Scambia et
al., 1996). The possibility that nm23 expression may have a
favourable significance in uterine tumours is also supported
by the data reported here. In our series, patients with high
levels of nm23 showed a lower incidence of lymph node
involvement as had already been reported in breast
(Bevilacqua et al., 1989) and ovarian cancer (Viel et al.,
1995). Moreover, a high level of nm23 is also correlated with
a lesser degree of myometrial invasion.
In conclusion, our data suggest that nm23 may play a role
in the biology of endometrial and cervical cancer and support
the undertaking ofmore extensive studies to evaluate whether
nm23 may be considered an important marker for defining
aggressiveness/metastatic potential of uterine tumours.
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